Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 98 articles:
HTML format
Text format



Single Articles


    January 2020
  1. SMALLEY I, Law V, Wyatt C, Evernden B, et al
    Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-2840.
    PubMed     Text format     Abstract available


    November 2019
  2. RIBAS A, Daud A, Pavlick AC, Gonzalez R, et al
    Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-4180.
    PubMed     Text format     Abstract available


  3. DIZIER B, Callegaro A, Debois M, Dreno B, et al
    A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-3717.
    PubMed     Text format     Abstract available


    October 2019
  4. KULKARNI PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, et al
    Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death.
    Clin Cancer Res. 2019 Oct 21. pii: 1078-0432.CCR-19-1495.
    PubMed     Text format     Abstract available


    September 2019
  5. NAMIKAWA K, Aung PP, Milton DR, Tetzlaff MT, et al
    Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma.
    Clin Cancer Res. 2019 Sep 30. pii: 1078-0432.CCR-19-1194.
    PubMed     Text format     Abstract available


  6. LUKE JJ, Olson DJ, Allred JB, Strand CA, et al
    Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201).
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1223.
    PubMed     Text format     Abstract available


  7. DI GIACOMO AM, Covre A, Finotello F, Rieder D, et al
    Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial.
    Clin Cancer Res. 2019 Sep 17. pii: 1078-0432.CCR-19-1335.
    PubMed     Text format     Abstract available


  8. THAKUR R, Laye JP, Lauss M, Diaz JMS, et al
    Transcriptomic analysis reveals prognostic molecular signatures of stage I melanoma.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-18-3659.
    PubMed     Text format     Abstract available


  9. EDWARDS J, Batten M, Ferguson A, Palendira U, et al
    Novel Immune Targets in Melanoma-Response.
    Clin Cancer Res. 2019;25:5424-5425.
    PubMed     Text format    


  10. NOCENTINI G, Cari L, Riccardi C
    Novel Immune Targets in Melanoma-Letter.
    Clin Cancer Res. 2019;25:5422-5423.
    PubMed     Text format    


    August 2019
  11. JIANG H, Shin DH, Nguyen TT, Fueyo J, et al
    Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Clin Cancer Res. 2019 Aug 27. pii: 1078-0432.CCR-19-0405.
    PubMed     Text format     Abstract available


  12. VASHISHT GOPAL YN, Gammon ST, Prasad R, Knighton B, et al
    A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0836.
    PubMed     Text format     Abstract available


  13. ALOIA A, Mullhaupt D, Chabbert CD, Eberhart T, et al
    A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0253.
    PubMed     Text format     Abstract available


  14. KONG Y, Yu J, Yan J, Guo Q, et al
    Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0475.
    PubMed     Text format     Abstract available


  15. PENG W, Williams LJ, Xu C, Melendez B, et al
    Anti-OX40 antibody directly enhances the function of tumor-reactive CD8(+) T cells and synergizes with PI3Kbeta inhibition in PTEN loss melanoma.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-1259.
    PubMed     Text format     Abstract available


    July 2019
  16. HAMID O, Molinero L, Bolen CR, Sosman JA, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-18-3488.
    PubMed     Text format     Abstract available


  17. FIELD MG, Kuznetsov JN, Bussies PL, Cai L, et al
    BAP1 loss is associated with DNA methylomic repatterning in highly aggressive Class 2 uveal melanomas.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0366.
    PubMed     Text format     Abstract available


    June 2019
  18. FAIAO-FLORES F, Emmons MF, Durante MA, Kinose F, et al
    HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3382.
    PubMed     Text format     Abstract available


  19. ANBUNATHAN H, Verstraten R, Singh AD, Harbour JW, et al
    Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10/BAF45a.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3052.
    PubMed     Text format     Abstract available


  20. RODRIGUES M, Mobuchon L, Houy A, Alsafadi S, et al
    Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-1215.
    PubMed     Text format     Abstract available


  21. TOKI MI, Merritt CR, Wong PF, Smithy JW, et al
    High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling.
    Clin Cancer Res. 2019 Jun 12. pii: 1078-0432.CCR-19-0104.
    PubMed     Text format     Abstract available


    May 2019
  22. LUKE JJ, Bao R, Sweis RF, Spranger S, et al
    WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Clin Cancer Res. 2019;25:3074-3083.
    PubMed     Text format     Abstract available


  23. GOFF SL, Rosenberg SA
    BRAF Inhibition: Bridge or Boost to T-cell Therapy?
    Clin Cancer Res. 2019;25:2682-2684.
    PubMed     Text format     Abstract available


    April 2019
  24. COHEN JV, Sullivan RJ
    Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-0836.
    PubMed     Text format     Abstract available


  25. SHOUSHTARI AN
    About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-19-0658.
    PubMed     Text format     Abstract available


  26. WU RY, Kong PF, Xia L, Huang Y, et al
    Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.
    Clin Cancer Res. 2019 Apr 2. pii: 1078-0432.CCR-18-2840.
    PubMed     Text format     Abstract available


    March 2019
  27. WEISS SA, Wolchok JD, Sznol M
    Immunotherapy of melanoma: facts and hopes.
    Clin Cancer Res. 2019 Mar 28. pii: 1078-0432.CCR-18-1550.
    PubMed     Text format     Abstract available


  28. YAN Y, Wongchenko MJ, Robert C, Larkin J, et al
    Genomic features of exceptional response in vemurafenib +/- cobimetinib-treated patients with BRAFV600-mutated metastatic melanoma.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-0720.
    PubMed     Text format     Abstract available


  29. JOHNSON DB, Balko JM
    Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
    Clin Cancer Res. 2019;25:1452-1454.
    PubMed     Text format     Abstract available


    February 2019
  30. ZHOU R, Shi C, Tao W, Li J, et al
    Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations.
    Clin Cancer Res. 2019 Feb 19. pii: 1078-0432.CCR-18-3442.
    PubMed     Text format     Abstract available


  31. EDWARDS JJ, Tasker A, Silva I, Quek C, et al
    Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma: implications for clinical trials.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-4011.
    PubMed     Text format     Abstract available


  32. ATAY C, Kwak T, Lavilla-Alonso S, Donthireddy L, et al
    BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.
    Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-2725.
    PubMed     Text format     Abstract available


    January 2019
  33. GARTRELL RD, Marks DK, Rizk EM, Bogardus M, et al
    Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-2847.
    PubMed     Text format     Abstract available


  34. PIRES DA SILVA I, Wang KYX, Wilmott JS, Holst J, et al
    Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Jan 10. pii: 1078-0432.CCR-18-1680.
    PubMed     Text format     Abstract available


  35. WONG PF, Wei W, Smithy JW, Acs B, et al
    Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2652.
    PubMed     Text format     Abstract available


    December 2018
  36. VAN MEIR EG, Dong L, You S, Zhang Q, et al
    Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1368.
    PubMed     Text format     Abstract available


  37. KIM SH, Roszik J, Cho SN, Ogata D, et al
    The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma.
    Clin Cancer Res. 2018 Dec 11. pii: 1078-0432.CCR-18-1163.
    PubMed     Text format     Abstract available


  38. JOSEPH RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, et al
    Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
    Clin Cancer Res. 2018;24:6098.
    PubMed     Text format    


    November 2018
  39. TARHINI AA, Lee SJ, Li X, Rao UN, et al
    E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-alpha2b in Advanced Melanoma.
    Clin Cancer Res. 2018 Nov 12. pii: 1078-0432.CCR-18-2258.
    PubMed     Text format     Abstract available


  40. LIM SY, Lee JH, Gide TN, Menzies AM, et al
    Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.
    Clin Cancer Res. 2018 Nov 8. pii: 1078-0432.CCR-18-2795.
    PubMed     Text format     Abstract available


    August 2018
  41. WOODS D, Ramakrishnan R, Laino AS, Berglund AE, et al
    Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T-cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-1100.
    PubMed     Text format     Abstract available


  42. GOTTESDIENER LS, O'Connor S, Busam KJ, Won H, et al
    Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-1397.
    PubMed     Text format     Abstract available


    July 2018
  43. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Text format     Abstract available


  44. JOHNSON DB, Dahlman KB
    Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1795.
    PubMed     Text format     Abstract available


  45. JOHNSON DB, Bordeaux JM, Kim JY, Vaupel CA, et al
    Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0309.
    PubMed     Text format     Abstract available


    June 2018
  46. PAWELEC G
    Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma?
    Clin Cancer Res. 2018 Jun 15. pii: 1078-0432.CCR-18-1475.
    PubMed     Text format     Abstract available


  47. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Text format     Abstract available


  48. WARNER AB, Postow MA
    Bigger is not always better: Tumor size and prognosis in advanced melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-18-1311.
    PubMed     Text format     Abstract available


    May 2018
  49. FORGET MA, Haymaker C, Hess KR, Meng YJ, et al
    Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-17-3649.
    PubMed     Text format     Abstract available


  50. BEZROOKOVE V, Nosrati M, Miller JR, de Semir D, et al
    Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0791.
    PubMed     Text format     Abstract available


  51. TEH JLF, Aplin AE
    Playing the melanoma endgame.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-18-0989.
    PubMed     Text format     Abstract available


    April 2018
  52. JOSEPH RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, et al
    Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-2386.
    PubMed     Text format     Abstract available


  53. EROGLU Z, Chen YA, Gibney GT, Weber JS, et al
    Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma.
    Clin Cancer Res. 2018 Apr 19. pii: 1078-0432.CCR-18-0565.
    PubMed     Text format     Abstract available


  54. SANLORENZO M, Vujic I, Floris A, Novelli M, et al
    BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-17-1914.
    PubMed     Text format     Abstract available


  55. YANG J, Hamid O, Carvajal RD
    The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.
    Clin Cancer Res. 2018 Apr 2. pii: 1078-0432.CCR-18-0020.
    PubMed     Text format     Abstract available


    March 2018
  56. EDWARDS J, Wilmott JS, Madore J, Gide TN, et al
    CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and expand significantly during anti-PD1 treatment.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2257.
    PubMed     Text format     Abstract available


  57. ZHANG G, Wu LW, Mender I, Barzily-Rokni M, et al
    Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2773.
    PubMed     Text format     Abstract available


  58. OO ZY, Stevenson AJ, Proctor MA, Daignault SM, et al
    Endogenous replication stress marks melanomas sensitive to CHK1 inhibitors in vivo.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2701.
    PubMed     Text format     Abstract available


    January 2018
  59. ATKINS MB, Hodi FS, Thompson JA, McDermott D, et al
    Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3436.
    PubMed     Text format     Abstract available


  60. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Text format     Abstract available


    December 2017
  61. JIN Y, Zhang P, Wang Y, Jin B, et al
    Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-1703.
    PubMed     Text format     Abstract available


    November 2017
  62. GIDE TN, Wilmott JS, Scolyer RA, Long GV, et al
    Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Clin Cancer Res. 2017 Nov 10. pii: clincanres.2267.2017.
    PubMed     Text format     Abstract available


    October 2017
  63. KOSTER BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, et al
    Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Clin Cancer Res. 2017;23:5679-5686.
    PubMed     Text format     Abstract available


    September 2017
  64. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Text format     Abstract available


    August 2017
  65. ENNEN M, Keime C, Gambi G, Kieny A, et al
    MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra and inter-tumoral heterogeneity of primary melanoma.
    Clin Cancer Res. 2017 Aug 28. pii: clincanres.0010.2017.
    PubMed     Text format     Abstract available


  66. KONG Y, Sheng X, Wu X, Yan J, et al
    Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy.
    Clin Cancer Res. 2017 Aug 22. pii: clincanres.0070.2017.
    PubMed     Text format     Abstract available


  67. KASHANI-SABET M, Nosrati M, Miller J, Sagebiel R, et al
    Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.1317.2017.
    PubMed     Text format     Abstract available


    July 2017
  68. NIESSNER H, Sinnberg T, Kosnopfel C, Smalley KSM, et al
    BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.0098.2017.
    PubMed     Text format     Abstract available


  69. KAKAVAND H, Rawson RV, Pupo GM, Yang JYH, et al
    PD-L1 expression and immune escape in melanoma resistanceto MAPK inhibitors.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.1688.2016.
    PubMed     Text format     Abstract available


  70. BAI X, Kong Y, Chi Z, Sheng X, et al
    MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients a retrospective study of 2793 cases.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.0980.2017.
    PubMed     Text format     Abstract available


    June 2017
  71. DELORD JP, Robert C, Nyakas M, McArthur GA, et al
    Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.2923.2016.
    PubMed     Text format     Abstract available


  72. NISHINO M, Giobbie-Hurder A, Manos MP, Bailey N, et al
    Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
    Clin Cancer Res. 2017 Jun 7. doi: 10.1158/1078-0432.CCR-17-0114.
    PubMed     Text format     Abstract available


    May 2017
  73. KULKARNI A, Al-Hraishawi H, Simhadri S, Hirshfield KM, et al
    BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V600E mutant melanoma.
    Clin Cancer Res. 2017 May 24. pii: clincanres.0758.2016.
    PubMed     Text format     Abstract available


  74. BUTTERFIELD LH, Zhao F, Lee S, Tarhini AA, et al
    Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697).
    Clin Cancer Res. 2017 May 23. pii: clincanres.3016.2016.
    PubMed     Text format     Abstract available


  75. WONGCHENKO MJ, McArthur GA, Dreno B, Larkin J, et al
    Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups With Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
    Clin Cancer Res. 2017 May 23. pii: clincanres.0172.2017.
    PubMed     Text format     Abstract available


  76. VILAIN RE, Menzies AM, Wilmott JS, Kakavand H, et al
    Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma.
    Clin Cancer Res. 2017 May 16. pii: clincanres.0698.2016.
    PubMed     Text format     Abstract available


  77. PARKHURST M, Gros A, Pasetto A, Prickett T, et al
    Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Clin Cancer Res. 2017;23:2491-2505.
    PubMed     Text format     Abstract available


  78. INFANTE JR, Hollebecque A, Postel-Vinay S, Bauer TM, et al
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
    Clin Cancer Res. 2017;23:2423-2432.
    PubMed     Text format     Abstract available


    April 2017
  79. FRIEDMAN AA, Xia Y, Trippa L, Le LP, et al
    Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.3029.2016.
    PubMed     Text format     Abstract available


  80. SUNSHINE JC, Nguyen P, Kaunitz G, Cottrell T, et al
    PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1821.2016.
    PubMed     Text format     Abstract available


  81. SEGAL NH, Logan TF, Hodi FS, McDermott D, et al
    Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
    Clin Cancer Res. 2017;23:1929-1936.
    PubMed     Text format     Abstract available


  82. IIDA Y, Ciechanover A, Marzese DM, Hata K, et al
    Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-kappaB Pathway in Melanoma.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.0146.2017.
    PubMed     Text format     Abstract available


    March 2017

  83. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  84. CHUK MK, Chang JT, Theoret MR, Sampene E, et al
    FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 24. pii: clincanres.0663.2016.
    PubMed     Text format     Abstract available


  85. BEHERA R, Kaur A, Webster MR, Kim S, et al
    Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho.
    Clin Cancer Res. 2017 Feb 23. pii: clincanres.0201.2017.
    PubMed     Text format     Abstract available


  86. EXLEY MA, Friedlander P, Alatrakchi N, Vriend L, et al
    Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.0600.2016.
    PubMed     Text format     Abstract available


  87. BARONE A, Hazarika M, Theoret MR, Mishra-Kalyani P, et al
    FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 8. pii: clincanres.0664.2016.
    PubMed     Text format     Abstract available


    January 2017
  88. DENIGER DC, Kwong ML, Pasetto A, Dudley ME, et al
    A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2017;23:351-362.
    PubMed     Text format     Abstract available


  89. HAZARIKA M, Chuk MK, Theoret MR, Mushti S, et al
    U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.0712.2016.
    PubMed     Text format     Abstract available


  90. BEAVER JA, Theoret MR, Mushti S, He K, et al
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.0714.2016.
    PubMed     Text format     Abstract available


    November 2016
  91. GANNON P, Baumgaertner P, Huber A, Iancu EM, et al
    Rapid and continued T cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients.
    Clin Cancer Res. 2016 Nov 21. pii: clincanres.1708.2016.
    PubMed     Text format     Abstract available


  92. NAGARAJAN P, Curry JL, Ning J, Piao J, et al
    Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016.
    PubMed     Text format     Abstract available


  93. SANGIOLO D, Gammaitoni L, Giraudo L, Macagno M, et al
    Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1524.2016.
    PubMed     Text format     Abstract available


  94. KHALIL DN, Postow MA, Ibrahim N, Ludwig DL, et al
    An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
    Clin Cancer Res. 2016;22:5204-5210.
    PubMed     Text format     Abstract available


    August 2016
  95. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


    April 2016
  96. KREPLER C, Xiao M, Sproesser K, Brafford PA, et al
    Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Clin Cancer Res. 2016;22:1592-602.
    PubMed     Text format     Abstract available


    March 2016
  97. KOHLHAPP FJ, Kaufman HL
    Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Clin Cancer Res. 2016;22:1048-54.
    PubMed     Text format     Abstract available


    February 2016
  98. CHARYCH DH, Hoch U, Langowski JL, Lee SR, et al
    NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
    Clin Cancer Res. 2016;22:680-90.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: